Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma

NCT00248534 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped slow accrual/lack of resources/low priority due to combining 2 consortia

Conditions

Lymphoma

Interventions

BIOLOGICAL: rituximab
DRUG: methylprednisolone
DRUG: temozolomide

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]